Corcept Therapeutics Sees Hedge Fund Boost in Q2 2025
Corcept Therapeutics Incorporated (NASDAQ:CORT), a biotech firm specialising in severe disorders, saw increased hedge fund interest in Q2 2025. 35 portfolios held the company, up from 33 in the previous quarter. Meanwhile, global markets thrived on U.S. trade deals and European stimulus expectations.
ClearBridge Global Value Improvers Strategy, in its Q2 2025 investor letter, highlighted Corcept Therapeutics. The strategy outperformed the MSCI World Value Index, boosted by strong contributions from industrials and IT holdings. Corcept's wider implications were noted, with a successful drug already in the market and an improved product in development.
The company reported revenue of $194.4 million in Q2 2025, up from $163.8 million in the same period last year. It was also a new addition to the portfolio, as mentioned in the second-quarter 2025 investor letter.
Corcept Therapeutics Incorporated's strong Q2 2025 performance and potential have drawn increased hedge fund interest. The company's revenue growth and promising pipeline have positioned it favourably in the market.
Read also:
- Germany Launches HoLa Project for Megawatt Charging on A2 Motorway
- Transforming Digital Inventories in the Food Industry: A Comprehensive Guide for Food Businesses
- Canada's Transportation Revolution: Hyperloop & Electric Air Taxis by 2026
- ACC Expands European Battery Production with Three New Gigafactories
